A parallel randomised phase II trial of CHOP chemotherapy with or without Bortezomib in relapsed mantle cell lymphoma

Trial Profile

A parallel randomised phase II trial of CHOP chemotherapy with or without Bortezomib in relapsed mantle cell lymphoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Sep 2013 Accrual to date is 55% according to United Kingdom Clinical Research Network.
    • 19 May 2013 Accrual to date is 54% according to United Kingdom Clinical Research Network.
    • 09 Feb 2013 Accrual to date is 53% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top